Some DD from last year.
On July 7, 2014 the Company announced that the European Patent Office has granted the
Company’s patent compositions and methods for treating fibroproliferative disorders.
This patent covers the composition and use of the combination of drugs used in the
Company’s lead product for treatment of IPF and includes claims for the use of the
combination to treat liver fibrosis, kidney fibrosis, uterine fibrosis and peripheral arterial
disease.
• On July 9, 2014 the Company released the results of its pre-clinical studies of PTL-202.
PTL-202 and its separate constituents were tested in 5 experiments in a recognized mouse
model of pulmonary fibrosis. These studies provided the data required for the recently
granted European patent covering the proprietary technology utilized in PTL-202.
• On July 16, 2014 the Company signed a term sheet with Vodis Innovative
Pharmaceuticals (“Vodis”) agreeing to work with Vodis on the development of therapies
based on extracts from cannabis plants.
Market Data 
Markets 
AI
